Literature DB >> 731214

Antibodies to single-stranded DNA: an aid in diagnosis of viral hepatitis.

V M Villarejos, P C Arquembourg, K A Visoná, A Gutiérrez.   

Abstract

In clinical and subclinical viral hepatitis a significant increase of antibodies to single-stranded DNA revealed by the prepatent stage of the disease before any elevation of serum transaminases. In type A hepatitis, a rise in anti-DNA titers was detectable one to two weeks before onset of clinical and biochemical signs; in type B hepatitis, the rise of anti-DNA coincided with or preceded the appearance of HBSAg, several weeks before the onset of clinical illness. In both hepatitis types anti-DNA titers reached a peak (640--2,560) at onset and dropped shortly after serum transaminases returned to normal at the end of acute illness. The anti-DNA response in non-A/non-B hepatitis was of similar magnitude. Anti-DNA elevation was the only positive sign found in most silent infections of either type that later showed specific seroconversion. Anti-DNA levels in noninfected contacts were in the same range as those found in a group of health individuals. The anti-DNA test is useful for early diagnosis of viral hepatitis and should be a valuable addition to current epidemiological and clinical procedures.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 731214     DOI: 10.1002/jmv.1890020409

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  2 in total

1.  Follow-up of antibodies against single-stranded DNA in patients with haematological malignancies.

Authors:  A A Kostiala; M Gripenberg; E Elonen; G Gripenberg; I Kostiala
Journal:  Clin Exp Immunol       Date:  1985-07       Impact factor: 4.330

2.  Detection of anti-double and anti-single stranded DNA antibodies in chronic liver disease: significance of anti-double stranded DNA antibody in autoimmune hepatitis.

Authors:  K Tsuchiya; K Kiyosawa; H Imai; T Sodeyama; S Furuta
Journal:  J Gastroenterol       Date:  1994-04       Impact factor: 7.527

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.